|
Human Genome Sciences Adopts Poison Pill to Thwart Glaxo Takeover - New York Times The biotechnology company Human Genome Sciences on Thursday adopted a shareholder rights plan, or poison pill, as it sought to fend off a $2.59 billion takeover offer from the drug maker GlaxoSmithKline. The news comes a week after Glaxo ... Posted on 17 May 2012 | 1:21 pm |
|
Therapure Recognized as Best in Canadian Biotechnology - Financial Post BIOTECanada announced earlier today Therapure Biopharma Inc. (Therapure) has been named recipient of a Gold Leaf Award recognizing an outstanding early stage health company. Therapure is being recognized for the potential of their highly ... Posted on 17 May 2012 | 1:07 pm |
|
Puma Biotechnology to Present Clinical Data on PB272 at ASCO 2012 Annual Meeting - Investors Business Daily LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (OTCBB: PBYI), a development stage biopharmaceutical company, announced that clinical data for its lead drug candidate PB272 (neratinib) in patients with metastatic breast cancer will be presented in ... Posted on 17 May 2012 | 10:58 am |
|
Panel of Top Industry Executives to Discuss Biotech and Big Pharma - What's Next? - 2012 BIO International Convention Keynote - TMCnet Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences Wednesday's Keynote session is sponsored by Amgen, a leading human therapeutics company in the biotechnology industry. Immediately preceding the Keynote panel ... Posted on 16 May 2012 | 11:31 pm |
|
Final Glance: Biotechnology companies - CBS News NEW YORK — Shares of some top biotechnology companies were mixed at the close of trading: Amgen Inc. rose $.30 or .4 percent, to $70.98. Biogen Idec fell $.24 or .2 percent, to $136.80. Celgene Corp. fell $.48 or .7 percent, to $70.72. Posted on 16 May 2012 | 10:55 pm |